A pharmacokinetic and pharmacodynamic study of a 'visiting pill' containing norethisterone.
The pharmacokinetics and pharmacodynamic effects of two doses of norethisterone (5mg and 3mg) used as a 'visiting pill' were investigated. There were no significant differences in the pharmacokinetics of the two doses except for the peak concentration achieved and the bioavailability as assessed by the area under the serum norethisterone concentration - time curve. Both doses were rapidly absorbed. Pharmacodynamic effects were minor. No change occurred in serum concentrations of total cholesterol, total triglycerides or HDL-cholesterol. The area under the serum glucose concentration--time curve and particularly the area under the serum insulin concentration--time curve were significantly increased as a result of treatment but no change occurred in the serum levels of glycosylated haemoglobin. SHBG concentrations in serum decreased on treatment whereas those of ceruloplasmin increased.
D000042:Absorption; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002570:Ceruloplasmin / Q000378:metabolism; D002681:China; D004958:Estradiol / Q000097:blood; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D007700:Kinetics; D008055:Lipids / Q000097:blood; D009640:Norethindrone / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism
D001786:Blood Glucose; D002570:Ceruloplasmin; D004958:Estradiol; D006442:Glycated Hemoglobin; D007328:Insulin; D008055:Lipids; D009640:Norethindrone; D011374:Progesterone; D012738:Sex Hormone-Binding Globulin